These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2149501)

  • 1. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
    Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate S
    Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
    Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
    Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate SL
    Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; Smith IE
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
    Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
    Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
    Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.
    Santen RJ
    Breast Cancer Res Treat; 1981; 1(3):183-202. PubMed ID: 6293627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
    Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
    Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
    Bruning PF; Bonfrer JM; Hart AA; van der Linden E; de Jong-Bakker M; Moolenaar AJ; Nooijen WJ
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):369-76. PubMed ID: 2702989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
    J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose aminoglutethimide in treatment of advanced breast cancer.
    Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
    Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
    Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
    Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
    Bruning PF; Bonfrer JM; De Jong-Bakker M; Nooyen W
    J Steroid Biochem; 1984 Sep; 21(3):293-8. PubMed ID: 6092781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
    Cocconi G; Bisagni G; Ceci G; Bacchi M; Boni C; Brugia M; Carpi A; Di Costanzo F; Franciosi V; Gori S
    J Clin Oncol; 1992 Jun; 10(6):984-9. PubMed ID: 1588379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer.
    Mercer PM; Ebbs SR; Fraser SC; Coltart RS; Bates T
    Eur J Surg Oncol; 1993 Jun; 19(3):254-8. PubMed ID: 8314383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
    Dowsett M; Harris AL; Smith IE; Jeffcoate SL
    Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
    Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
    J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
    Dowsett M; Harris AL; Smith IE; Jeffcoate SL
    J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.